Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Julie Perry, Selma Osman, Jim A. Wright, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0266852-e0266852
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
Ana Atti, Ferdinando Insalata, Edward J Carr, et al.
Journal of Infection (2022) Vol. 85, Iss. 5, pp. 545-556
Open Access | Times Cited: 39
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
Brechje de Gier, Anne J. Huiberts, Christina E. Hoeve, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
Tomer Hertz, Shlomia Levy, Daniel Ostrovsky, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies
Nathan J. Cheetham, Milla Kibble, Andrew Wong, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 24
Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70
Byron Brook, Valérie Duval, Soumik Barman, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 757
Closed Access | Times Cited: 9
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
Beatriz Escudero-Pérez, Philip Lawrence, Javier Castillo‐Olivares
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
José Víctor Zambrana, Ian A. Mellis, Abigail Shotwell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Association of infection-induced antibody levels with risk of subsequent SARS–COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020–17 February 2021
Jianrong Shi, Myra Gayle Gabriel, Monica Epperson, et al.
Microbiology Spectrum (2025)
Open Access
Uncertainty quantification of antibody measurements: Physical principles and implications for standardization
Paul N. Patrone, Lili Wang, Sheng Lin‐Gibson, et al.
Physical review. E (2025) Vol. 111, Iss. 2
Closed Access
Advances in Surrogate Neutralization Tests for High-Throughput Screening and the Point-of-Care
Simon Streif, Antje J. Baeumner
Analytical Chemistry (2025)
Open Access
Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection
Javier Perez‐Saez, María-Eugenia Zaballa, Julien Lamour, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Rituparna Das, Randall N. Hyer, Paul R. Burton, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 12
Anti-nucleocapsid antibody levels following initial and repeat SARS-CoV-2 infections in a cohort of long-term care facility residents in England (VIVALDI)
Oliver Stirrup, Gokhan Tut, Maria Krutikov, et al.
Wellcome Open Research (2024) Vol. 9, pp. 45-45
Open Access | Times Cited: 4
The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis
Qi Chen, Kongxin Zhu, Xiaohui Liu, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 793-803
Open Access | Times Cited: 20
Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273
Samuel M. Ailsworth, Behnam Keshavarz, Nathan E. Richards, et al.
Annals of Allergy Asthma & Immunology (2022) Vol. 130, Iss. 1, pp. 67-73
Open Access | Times Cited: 18
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, et al.
International Journal of Infectious Diseases (2023) Vol. 128, pp. 347-354
Open Access | Times Cited: 10
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Anoop Kumar, Prajna Tripathi, Prashant Kumar, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 459-459
Open Access | Times Cited: 3
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
Luigi Aurisicchio, Nadia Brambilla, Marina Elena Cazzaniga, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 788-800
Open Access | Times Cited: 15
A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study
Emily J. Doucette, Joslyn Gray, Kevin Fonseca, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0284046-e0284046
Open Access | Times Cited: 8
SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
Annapaola Santoro, Andrea Capri, Daniele Petrone, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1247-1247
Open Access | Times Cited: 8
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency
Anna M. Zhang, Ahmed Elmoursi, Daniel DiGiacomo, et al.
Journal of Allergy and Clinical Immunology Global (2024) Vol. 3, Iss. 2, pp. 100234-100234
Open Access | Times Cited: 2
Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy
Min Joo Choi, Hakjun Hyun, Jung Yeon Heo, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27211-e27211
Open Access | Times Cited: 2
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection
Joanne Byrne, Lili Gu, A. Léon, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Time to address quality control processes applied to antibody testing for infectious diseases
Wayne Dimech, Giuseppe A. Vincini, Mario Plebani, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2022) Vol. 61, Iss. 2, pp. 205-212
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top